DHA alters expression of target proteins of cancer therapy in chemotherapy resistant SW620 colon cancer cells

Nutrition and Cancer

Volumn 62, Issue 5, 2010, Pages 611-621

  Slagsvold, Jens E ^a   Pettersen, Caroline H H ^a   Strvold, Gro L ^a   Follestad, Turid ^a   Krokan, Hans E ^a   Schnberg, Svanhild A ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; CELL DIVISION CYCLE 25 HOMOLOG; CYCLIN DEPENDENT KINASE 1; DOCOSAHEXAENOIC ACID; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIVIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; OMEGA 3 FATTY ACID; PROTEIN P21; STRATIFIN; SURVIVIN; UNCLASSIFIED DRUG; CDC25C PROTEIN, HUMAN; PROTEIN TYROSINE PHOSPHATASE; TRANSCRIPTION FACTOR RELA;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CHEMOSENSITIVITY; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IN VIVO STUDY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; APOPTOSIS; CHEMISTRY; COLONIC NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CDC2 PROTEIN KINASE; CDC25 PHOSPHATASES; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOCOSAHEXAENOIC ACIDS; DRUG RESISTANCE, NEOPLASM; G1 PHASE; G2 PHASE; HUMANS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; TRANSCRIPTION FACTOR RELA;

EID: 77954022595     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580903532366     Document Type: Article

References (98)

1. von Schacky C and Harris WS: Cardiovascular benefits of omega-3 fatty acids. Cardiovasc Res 73, 310-315, 2007.
2. Carpentier YA, Portois L, and Malaisse WJ: n-3 fatty acids and the metabolic syndrome. Am J Clin Nutr 83, 1499S-1504S, 2006.
3. Barre DE: The role of consumption of alpha-linolenic, eicosapentaenoic and docosahexaenoic acids in human metabolic syndrome and type 2 diabetes-a mini-review. J Oleo Sci 56, 319-325, 2007.
4. Calder PC: n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 83, 1505S-1519S, 2006.
5. Terry PD, Rohan TE, and Wolk A: Intakes of fish and marine fatty acids and the risks of cancers of the breast and prostate and of other hormonerelated cancers: a review of the epidemiologic evidence. Am J Clin Nutr 77, 532-543, 2003.
6. Colomer R,Moreno-Nogueira JM, Garcia-Luna PP, Garcia-Peris P,Garciade- Lorenzo A, et al.: N-3 fatty acids, cancer and cachexia: a systematic review of the literature. Br J Nutr 97, 823-831, 2007.
7. MacLean CH, Newberry SJ,Mojica WA, Khanna P, Issa AM, et al.: Effects of omega-3 fatty acids on cancer risk: a systematic review. JAMA 295, 403-415, 2006.
8. Caygill CP, Charlett A, and Hill MJ: Fat, fish, fish oil, and cancer. Br J Cancer 74, 159-164, 1996.
9. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, et al.: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18, 581-592, 2007.
10. Tebbutt NC, Cattell E, Midgley R, Cunningham D, and Kerr D: Systemic treatment of colorectal cancer. Eur J Cancer 38, 1000-1015, 2002.
11. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, et al.: Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 9, 730-756, 2008.
12. Falconer JS, Ross JA, Fearon KC, Hawkins RA, O'Riordain MG, et al.: Effect of eicosapentaenoic acid and other fatty acids on the growth in vitro of human pancreatic cancer cell lines. Br J Cancer 69, 826-832, 1994.
13. Finstad HS, Drevon CA, Kulseth MA, Synstad AV, Knudsen E, et al.: Cell proliferation, apoptosis and accumulation of lipid droplets in U937-1 cells incubated with eicosapentaenoic acid. Biochem J 336(Pt 2), 451-459, 1998.
14. Danbara N, Yuri T, Tsujita-Kyutoku M, Sato M, Senzaki H, et al.: Conjugated docosahexaenoic acid is a potent inducer of cell cycle arrest and apoptosis and inhibits growth of colo 201 human colon cancer cells. Nutr Cancer 50, 71-79, 2004.
15. Hardman WE, Sun L, Short N, and Cameron IL: Dietary omega-3 fatty acids and ionizing irradiation on human breast cancer xenograft growth and angiogenesis. Cancer Cell Int 5, 12, 2005.
16. Finstad HS, Myhrstad MC, Heimli H, Lomo J, Blomhoff HK, et al.: Multiplication and death-type of leukemia cell lines exposed to very long-chain polyunsaturated fatty acids. Leukemia 12, 921-929, 1998.
17. Kato T, Kolenic N, and Pardini RS: Docosahexaenoic acid (DHA), a primary tumor suppressive omega-3 fatty acid, inhibits growth of colorectal cancer independent of p53 mutational status. Nutr Cancer 58, 178-187, 2007.
18. Dekoj T, Lee S, Desai S, Trevino J, Babcock TA, et al.: G2/M cell-cycle arrest and apoptosis by n-3 fatty acids in a pancreatic cancer model. J Surg Res 139, 106-112, 2007.
19. Stoll BA: N-3 fatty acids and lipid peroxidation in breast cancer inhibition. Br J Nutr 87, 193-198, 2002.
20. Finstad HS, Kolset SO, Holme JA, Wiger R, Farrants AK, et al.: Effect of n-3 and n-6 fatty acids on proliferation and differentiation of promyelocytic leukemic HL-60 cells. Blood 84, 3799-3809, 1994.
21. Schonberg SA, Lundemo AG, Fladvad T, Holmgren K, Bremseth H, et al.: Closely related colon cancer cell lines display different sensitivity to polyunsaturated fatty acids, accumulate different lipid classes and downregulate sterol regulatory element-binding protein 1. FEBS J 273, 2749-2765, 2006.
22. Chawla A, Repa JJ, Evans RM, andMangelsdorf DJ: Nuclear receptors and lipid physiology: opening the X-files. Science 294, 1866-1870, 2001.
23. Fan YY, Spencer TE, Wang N, Moyer MP, and Chapkin RS: Chemopreventive n-3 fatty acids activate RXRalpha in colonocytes. Carcinogenesis 24, 1541-1548, 2003.
24. Forman BM, Chen J, and Evans RM: Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferatoractivated receptors alpha and delta. Proc Natl Acad SciUSA 94, 4312-4317, 1997.
25. Xu HE, Lambert MH,Montana VG, ParksDJ, Blanchard SG, et al.:Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 3, 397-403, 1999.
26. Collett ED,Davidson LA, Fan YY, Lupton JR, and Chapkin RS: n-6 and n-3 polyunsaturated fatty acids differentially modulate oncogenicRas activation in colonocytes. Am J Physiol Cell Physiol 280, C1066-C1075, 2001.
27. Calviello G, Serini S, Piccioni E, and Pessina G: Antineoplastic effects of n-3 polyunsaturated fatty acids in combinationwith drugs and radiotherapy: preventive and therapeutic strategies. Nutr Cancer 61, 287-301, 2009.
28. Jakobsen CH, Storvold GL, Bremseth H, Follestad T, Sand K, et al.: DHA induces ER stress and growth arrest in human colon cancer cells: associations with cholesterol and calcium homeostasis. J Lipid Res 49, 2089-2100, 2008.
29. Slagsvold JE, Pettersen CH, Follestad T, Krokan HE, and Schonberg SA: The antiproliferative effect of EPA in HL60 cells is mediated by alterations in calcium homeostasis. Lipids 44, 103-113, 2009.
30. JohanssonMand Persson JL: Cancer therapy: targeting cell cycle regulators. Anticancer Agents Med Chem 8, 723-731, 2008.
31. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, et al.: IAPtargeted therapies for cancer. Oncogene 27, 6252-6275, 2008.
32. Biondo PD, Brindley DN, Sawyer MB, and Field CJ: The potential for treatment with dietary long-chain polyunsaturated n-3 fatty acids during chemotherapy. J Nutr Biochem 19, 787-796, 2008.
33. Shaikh IA, Brown I, Schofield AC, Wahle KW, and Heys SD: Docosahexaenoic acid enhances the efficacy of docetaxel in prostate cancer cells by modulation of apoptosis: the role of genes associated with the NF-kappaB pathway. Prostate 68, 1635-1646, 2008.
34. Benais-Pont G, Dupertuis YM, Kossovsky MP, Nouet P, Allal AS, et al.: Omega-3 polyunsaturated fatty acids and ionizing radiation: combined cytotoxicity on human colorectal adenocarcinoma cells. Nutrition 22, 931-939, 2006.
35. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al.: Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31, e15, 2003.
36. Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3, Article 3, 2004.
37. Benjamini Y and Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Statistical Soc B 57, 289-300, 1995.
38. Langaas M, Lindqvist B, and Ferkingstad E: Estimating the proportion of true null hypotheses, with application to DNA microarray data. J Royal Statistical Soc B 67, 555-572, 2005.
39. Gentleman RC, Carey VJ, Bates DM, Bolstad B, DettlingM, et al.: Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5, R80, 2004.
40. Karin M and Lin A: NF-kappaB at the crossroads of life and death. Nat Immunol 3, 221-227, 2002.
41. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, et al.: Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factorkappaB- regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 109, 2293-2302, 2007.
42. Leibovitz A, Stinson JC, McCombsWB 3rd,McCoy CE,Mazur KC, et al.: Classification of human colorectal adenocarcinoma cell lines. Cancer Res 36, 4562-4569, 1976.
43. Hewitt RE, McMarlin A, Kleiner D, Wersto R, Martin P, et al.: Validation of a model of colon cancer progression. J Pathol 192, 446-454, 2000.
44. Huerta S, Harris DM, Jazirehi A, Bonavida B, Elashoff D, et al.: Gene expression profile of metastatic colon cancer cells resistant to cisplatininduced apoptosis. Int J Oncol 22, 663-670, 2003.
45. Huerta S, Heinzerling JH, Anguiano-Hernandez YM, Huerta-Yepez S, Lin J, et al.: Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF. J Surg Res 142, 184-194, 2007.
46. Toit-Kohn JL, Louw L, and Engelbrecht AM: Docosahexaenoic acid induces apoptosis in colorectal carcinoma cells by modulating the PI3 kinase and p38 MAPK pathways. J Nutr Biochem 20, 106-114, 2009.
47. Serini S, Piccioni E, Merendino N, andCalviello G: Dietary polyunsaturated fatty acids as inducers of apoptosis: implications for cancer. Apoptosis 14, 135-152, 2009.
48. Schroder M: Endoplasmic reticulum stress responses. Cell Mol Life Sci 65, 862-894, 2008.
49. Albino AP, Juan G, Traganos F, Reinhart L, Connolly J, et al.: Cell cycle arrest and apoptosis of melanoma cells by docosahexaenoic acid: association with decreased pRb phosphorylation. Cancer Res 60, 4139-4145, 2000.
50. Siddiqui RA, Jenski LJ, Harvey KA,Wiesehan JD, Stillwell W, et al.: Cellcycle arrest in Jurkat leukaemic cells: a possible role for docosahexaenoic acid. Biochem J 371, 621-629, 2003.
51. Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13, 1501-1512, 1999.
52. Taylor WR and Stark GR: Regulation of the G2/M transition by p53. Oncogene 20, 1803-1815, 2001.
53. Cayrol C, Knibiehler M, and Ducommun B: p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 16, 311-320, 1998.
54. Medema RH,Klompmaker R, Smits VA, and RijksenG: p21waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases. Oncogene 16, 431-441, 1998.
55. Cheng L, Pan CX, Zhang JT, Zhang S, Kinch MS, et al.: Loss of 14-3-3sigma in prostate cancer and its precursors. Clin Cancer Res 10, 3064-3068, 2004.
56. Vercoutter-Edouart AS, Lemoine J, Le Bourhis X, Louis H, Boilly B, et al.: Proteomic analysis reveals that 14-3-3sigma is down-regulated in human breast cancer cells. Cancer Res 61, 76-80, 2001.
57. Melis R and White R: Characterization of colonic polyps by twodimensional gel electrophoresis. Electrophoresis 20, 1055-1064, 1999.
58. Perathoner A, Pirkebner D, Brandacher G, Spizzo G, Stadlmann S, et al.: 14-3-3sigma expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Clin Cancer Res 11, 3274-3279, 2005.
59. Waldman T, Lengauer C, Kinzler KW, and Vogelstein B: Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381, 713-716, 1996.
60. Heerdt BG, Houston MA, and Augenlicht LH: Short-chain fatty acidinitiated cell cycle arrest and apoptosis of colonic epithelial cells is linked to mitochondrial function. Cell Growth Differ 8, 523-532, 1997.
61. Calviello G, Resci F, Serini S, Piccioni E, Toesca A, et al.: Docosahexaenoic acid induces proteasome-dependent degradation of beta-catenin, down-regulation of survivin and apoptosis in human colorectal cancer cells not expressing COX-2. Carcinogenesis 28, 1202-1209, 2007.
62. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, et al.: Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58, 5071-5074, 1998.
63. Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, et al.: Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 59, 1406-1412, 2002.
64. Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, et al.: Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 95, 92-95, 2001.
65. Rodel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, et al.: Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 65, 4881-4887, 2005.
66. LaCasse EC, Baird S, Korneluk RG, and MacKenzie AE: The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17, 3247-3259, 1998.
67. Chang H and Schimmer AD: Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment ofmalignancy. MolCancer Ther 6, 24-30, 2007.
68. Ashhab Y, Alian A, Polliack A, Panet A, and Ben Yehuda D: Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett 495, 56-60, 2001.
69. Wang R, Lin F, Wang X, Gao P, Dong K, et al.: Silencing Livin gene expression to inhibit proliferation and enhance chemosensitivity in tumor cells. Cancer Gene Ther 15, 402-412, 2008.
70. Malhotra JD and Kaufman RJ: The endoplasmic reticulum and the unfolded protein response. Semin Cell Dev Biol 18, 716-731, 2007.
71. Ma Y, Brewer JW, Diehl JA, and Hendershot LM: Two distinct stress signaling pathways converge upon the CHOP promoter during the mammalian unfolded protein response. J Mol Biol 318, 1351-1365, 2002.
72. McCullough KD, Martindale JL, Klotz LO, Aw TY, and Holbrook NJ: Gadd153 sensitizes cells to endoplasmic reticulum stress by downregulating Bcl2 and perturbing the cellular redox state. Mol Cell Biol 21, 1249-1259, 2001.
73. Heath-Engel HM, Chang NC, and Shore GC: The endoplasmic reticulum in apoptosis and autophagy: role of the BCL-2 protein family. Oncogene 27, 6419-6433, 2008.
74. Kim R, Ohi Y, Inoue H, Aogi K, and Toge T: Introduction of gadd153 gene into gastric cancer cells can modulate sensitivity to anticancer agents in association with apoptosis. Anticancer Res 19, 1779-1783, 1999.
75. Los G, Benbatoul K, Gately DP, Barton R, Christen R, et al.: Quantitation of the change in GADD153 messenger RNA level as a molecular marker of tumor response in head and neck cancer. Clin Cancer Res 5, 1610-1618, 1999.
76. de las Alas MM, Christen RD, Gately DP, Weiner DE, Benbatoul K, et al.: Increase in tumor GADD153 mRNA level following treatment correlates with response to paclitaxel. Cancer Chemother Pharmacol 45, 381-388, 2000.
77. Schley PD, Brindley DN, and Field CJ: (n-3) PUFA alter raft lipid composition and decrease epidermal growth factor receptor levels in lipid rafts of human breast cancer cells. J Nutr 137, 548-553, 2007.
78. Krishna M and Narang H: The complexity of mitogen-activated protein kinases (MAPKs) made simple. Cell Mol Life Sci 65, 3525-3544, 2008.
79. Iyoda K, Sasaki Y, Horimoto M, Toyama T, Yakushijin T, et al.: Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer 97, 3017-3026, 2003.
80. Maytin EV, Ubeda M, Lin JC, and Habener JF: Stress-inducible transcription factor CHOP/gadd153 induces apoptosis in mammalian cells via p38 kinase-dependent and -independent mechanisms. Exp Cell Res 267, 193-204, 2001.
81. Olson JMand Hallahan AR: p38MAPkinase: a convergence point in cancer therapy. Trends Mol Med 10, 125-129, 2004.
82. Bradham C and McClay DR: p38 MAPK in development and cancer. Cell Cycle 5, 824-828, 2006.
83. Horia E andWatkins BA: Complementary actions of docosahexaenoic acid and genistein on COX-2, PGE2 and invasiveness in MDA-MB-231 breast cancer cells. Carcinogenesis 28, 809-815, 2007.
84. Hering J, Garrean S, Dekoj TR, Razzak A, Saied A, et al.: Inhibition of proliferation by omega-3 fatty acids in chemoresistant pancreatic cancer cells. Ann Surg Oncol 14, 3620-3628, 2007.
85. HaydenMS,West AP, and Ghosh S: NF-kappaB and the immune response. Oncogene 25, 6758-6780, 2006.
86. Carmody RJ and Chen YH: Nuclear factor-kappaB: activation and regulation during toll-like receptor signaling. Cell Mol Immunol 4, 31-41, 2007.
87. Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B, et al.: NF-kappaB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev 12, 73-90, 2001.
88. Zhu L, Fukuda S, Cordis G, Das DK, and Maulik N: Anti-apoptotic protein survivin plays a significant role in tubular morphogenesis of human coronary arteriolar endothelial cells by hypoxic preconditioning. FEBS Lett 508, 369-374, 2001.
89. Rayet B and Gelinas C: Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18, 6938-6947, 1999.
90. Karin M: Nuclear factor-kappaB in cancer development and progression. Nature 441, 431-436, 2006.
91. Lee CH, Jeon YT, Kim SH, and Song YS: NF-kappaB as a potential molecular target for cancer therapy. Biofactors 29, 19-35, 2007.
92. Nakanishi C and Toi M: Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5, 297-309, 2005.
93. Weston VJ, Austen B, Wei W, Marston E, Alvi A, et al.: Apoptotic resistance to ionizing radiation in pediatric B-precursor acute lymphoblastic leukemia frequently involves increased NF-kappaB survival pathway signaling. Blood 104, 1465-1473, 2004.
94. Lagadec P, Griessinger E, Nawrot MP, Fenouille N, Colosetti P, et al.: Pharmacological targeting of NF-kappaB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells. Br J Cancer 98, 335-344, 2008.
95. Voboril R, Hochwald SN, Li J, Brank A, Weberova J, et al.: Inhibition of NF-kappa B augments sensitivity to 5-fluorouracil/folinic acid in colon cancer. J Surg Res 120, 178-188, 2004.
96. Camp ER, Li J, Minnich DJ, Brank A, Moldawer LL, et al.: Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer. J Am Coll Surg 199, 249-258, 2004.
97. Zhuo Z, Zhang L, Mu Q, Lou Y, Gong Z, et al.: The effect of combination treatment with docosahexaenoic acid and 5-fluorouracil on the mRNA expression of apoptosis-related genes, including the novel gene BCL2L12, in gastric cancer cells. In Vitro Cell Dev Biol Anim 45, 69-74, 2009.
98. Zand H, Rahimipour A, Salimi S, and Shafiee SM: Docosahexaenoic acid sensitizes Ramos cells to Gamma-irradiation-induced apoptosis through involvement of PPAR-gamma activation and NF-kappaB suppression. Mol Cell Biochem 317, 113-120, 2008.